SCARNA9L: A Potential Drug Target and Biomarker (G100158262)

Target Name: SCARNA9L

NCBI ID: G100158262

SCARNA9L

Other Name(s): small Cajal body-specific RNA 9 like | Small Cajal body-specific RNA 9 like

SCARNA9L: A Potential Drug Target and Biomarker

Scarna9l is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the Scarna family, which includes proteins that are involved in the development and maintenance of tissues. The Scarna9l protein has been identified as a potential drug target and biomarker due to its unique structure and the involvement of various cellular processes.

Structure and Function

The Scarna9l protein is a transmembrane protein that is expressed in various tissues of the body. It has a unique structure that consists of four transmembrane domains and an extracellular domain. The transmembrane domains are involved in the protein's stability and function, while the extracellular domain is involved in its interactions with other proteins and the cell surface.

The Scarna9l protein is involved in various cellular processes, including cell signaling, cell adhesion, and cell migration. It is a positive regulator of the Shc/FAK signaling pathway, which is involved in the development and maintenance of tissues. The Scarna9l protein helps to regulate the activity of the Shc protein, which is a negative regulator of the FAK signaling pathway.

The Scarna9l protein is also involved in the regulation of cell proliferation and cell differentiation. It has been shown to play a role in the development and maintenance of cancer cells, and it is a potential drug target for cancer therapies.

Drug Target Potential

The Scarna9l protein is a potential drug target due to its involvement in various cellular processes that are involved in cancer development. Cancer cells have the ability to evade the immune system and continue to grow and multiply, which is a major problem in the development and treatment of cancer. The Scarna9l protein is involved in the regulation of cell adhesion, which is a critical process for cancer cell survival.

The Scarna9l protein is also involved in the regulation of cell migration, which is a critical process for cancer cell invasion and metastasis. Cancer cells have the ability to migrate through the body and spread to other organs, which is a major problem in the development and treatment of cancer.

Biomarker Potential

The Scarna9l protein is also a potential biomarker for cancer. The Scarna9l protein is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract, which makes it a potential biomarker for cancer. The expression of the Scarna9l protein is also increased in various types of cancer, which could make it a useful biomarker for cancer diagnosis and monitoring.

Conclusion

The Scarna9l protein is a unique protein that is involved in various cellular processes in the body. Its structure and function are involved in the development and maintenance of tissues, and it is a potential drug target and biomarker for cancer. Further research is needed to fully understand the role of the Scarna9l protein in various cellular processes and its potential as a drug target and biomarker for cancer.

Protein Name: Small Cajal Body-specific RNA 9 Like

The "SCARNA9L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCARNA9L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets